Abstract

This is the third in a series of articles highlighting points raised in the King's Fund report on polypharmacy. This article highlights issues relating to medicines optimisation.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call